Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine
We describe characteristics of the first 1,000 mpox cases in the Netherlands, reported between 20 May and 8 August 2022, within the context of the public health response. These cases were predominantly men who have sex with men aged 31–45 years. The vast majority of infections were acquired through sexual contact with casual partners in private or recreational settings including LGBTQIA+ venues in the Netherlands. This indicates that, although some larger upsurges occurred from point-source and/or travel-related events, the outbreak was mainly characterised by sustained transmission within the Netherlands. In addition, we estimated the protective effect of first-generation smallpox vaccine against moderate/severe mpox and found a vaccine effectiveness of 58% (95% CI: 17–78%), suggesting moderate protection against moderate/severe mpox symptoms on top of any possible protection by this vaccine against MPXV infection and disease. Communication with and supporting the at-risk population in following mitigation measures remains essential.
Source: Eurosurveillance - Category: Infectious Diseases Authors: Catharina E van Ewijk, Fuminari Miura, Gini van Rijckevorsel, Henry JC de Vries, Matthijs RA Welkers, Oda E van den Berg, Ingrid HM Friesema, Patrick R van den Berg, Thomas Dalhuisen, Jacco Wallinga, Diederik Brandwagt, Brigitte AGL van Cleef, Harry Venne Source Type: research
More News: Infectious Diseases | International Medicine & Public Health | Monkeypox | Netherlands Health | Outbreaks | Smallpox | Smallpox Vaccine | Vaccines